.

Investor

OncoCyte Senior Management Rings NYSE Opening Bell

OncoCyte Chairman and CEO at Bell ringing ceremony

Investment Highlights
Pipeline positioned to capitalize on standard of care moving to liquid biopsy
Early diagnosis focused on the largest market segment with the greatest unmet needs
Clinical data demonstrates strong assay performance
Compelling value proposition for healthcare providers, patients, and payers
Strong leadership with commercialization experience
Stock Information
Events & Presentation

No upcoming events scheduled at this time.

Latest News
OncoCyte to Report Second Quarter Financial Results on August 14, 2017
OncoCyte Receives $5.74 Million in Proceeds from Exercise of Warrants